Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25222669 | 0.92 | PIK3CA (0.60) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25685461 | 0.87 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25682965 | 0.86 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL31516558 | 0.85 | PIK3CA (0.61) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25682966 | 0.84 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25685464 | 0.84 | PIK3CA (0.63) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25683183 | 0.83 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25685462 | 0.82 | PIK3CA (0.55) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL25683208 | 0.82 | PIK3CA (0.53) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25683186 | 0.81 | PIK3CA (0.54) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PIK3CA 2127/4885PIK3CB 877/4885PIK3CD 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.